Lupus is treated with a combination of medications tailored to how severe the disease is and which organs are affected. Nearly every lupus patient starts with hydroxychloroquine, an antimalarial drug recommended for all people with lupus unless they have a specific reason they can’t take it. From there, treatment can expand to include steroids, immunosuppressants, and newer biologic drugs depending on how the disease responds.
Hydroxychloroquine: The Foundation of Lupus Treatment
Hydroxychloroquine is the single most important medication in lupus management. International treatment guidelines recommend it for every lupus patient, regardless of disease severity. It reduces flares, protects against organ damage over time, and helps control joint pain, skin rashes, and fatigue. The recommended dose is 5 mg per kilogram of your actual body weight per day, a threshold set to balance effectiveness against the risk of eye toxicity with long-term use.
One thing to know upfront: hydroxychloroquine is slow to kick in. It takes several weeks to start working, and you may not feel its full benefit for three to six months. That lag time can be frustrating, but the drug’s long-term protective effects are well established. Many people stay on it for years or even indefinitely.
The main long-term concern is retinal toxicity, a rare but serious side effect that can affect vision. The American Academy of Ophthalmology recommends a baseline eye exam when you start the drug, including optical coherence tomography (OCT) and fundus imaging. After that, annual eye screening is recommended, though it can be deferred during the first five years if you don’t have additional risk factors like kidney disease or higher dosing.
Corticosteroids for Flares and Active Disease
When lupus flares or hydroxychloroquine alone isn’t enough, corticosteroids like prednisone are the fastest way to bring inflammation under control. The dose depends on what’s happening: mild joint or skin symptoms might need only a low dose, while serious organ involvement can call for high-dose intravenous pulses given over one to three days in a hospital setting.
The catch with steroids is that staying on them long-term causes real harm. Bone loss, weight gain, high blood sugar, cataracts, and increased infection risk all climb with prolonged use. Current guidelines push hard to get the daily dose down to 5 mg of prednisone or less, and ideally to stop steroids entirely when possible. More than 40% of lupus specialists surveyed said they prefer to keep patients at 5 mg per day when the disease is quiet but blood tests still show activity, reflecting how tricky it can be to come off steroids without triggering a flare.
Immunosuppressants for Moderate to Severe Lupus
If hydroxychloroquine and low-dose steroids aren’t controlling your symptoms, or if you can’t taper steroids low enough, the next step is adding an immunosuppressant. The three most commonly used are methotrexate, azathioprine, and mycophenolate. Each works by dialing down your immune system’s overactivity, but they’re used in slightly different situations.
Methotrexate tends to be favored for joint and skin symptoms. Most people notice improvements within three to six weeks, though the full effect can take up to three months. Azathioprine is slower, often taking 6 to 12 weeks to show results, and is frequently used for long-term maintenance. Mycophenolate is particularly important in kidney involvement and has become a cornerstone of lupus nephritis treatment.
For organ-threatening or life-threatening disease, cyclophosphamide is a more powerful option. It’s typically given intravenously and reserved for serious situations like severe kidney inflammation, lung involvement, or nervous system disease. Because of its significant side effects, including infection risk and potential impact on fertility, it’s used as a short-term induction treatment and then swapped for a gentler drug like mycophenolate or azathioprine for ongoing maintenance.
Biologic Therapies
Biologics are newer, targeted drugs that block specific parts of the immune system rather than suppressing it broadly. Two are currently approved for systemic lupus: belimumab and anifrolumab.
Belimumab (sold as Benlysta) works by blocking a protein called BAFF that helps certain immune cells survive and multiply. In lupus, these cells are overactive and produce the antibodies that attack your own tissues. By cutting off their survival signal, belimumab reduces disease activity over time. It can be given as an intravenous infusion every four weeks or as a weekly injection you administer yourself at home. Belimumab is used on top of standard therapy for patients whose disease isn’t adequately controlled, and it also plays a role in treating lupus nephritis.
Anifrolumab (Saphnelo) takes a different approach, blocking the receptor for type I interferon, a group of immune signaling molecules that are abnormally elevated in most lupus patients. It’s given as an intravenous infusion every four weeks. A self-injectable subcutaneous version has completed clinical trials with positive results and is currently under FDA review, which would make it more convenient for patients.
Medications Specifically for Lupus Nephritis
When lupus attacks the kidneys, treatment intensifies significantly. Lupus nephritis is one of the most serious complications of the disease, and the medication strategy has its own specific playbook.
Initial treatment typically combines either mycophenolate or intravenous cyclophosphamide with steroid pulses. On top of that foundation, guidelines now recommend adding either belimumab or a calcineurin inhibitor like voclosporin to improve outcomes. In clinical trials, adding voclosporin to mycophenolate and steroids nearly doubled the rate of complete kidney response at one year: 41% of patients achieved it compared to 23% on mycophenolate and steroids alone.
Obinutuzumab (Gazyva) received FDA approval in October 2025 specifically for active lupus nephritis, adding another option for this difficult-to-treat complication. It works by depleting a type of immune cell called B cells, similar in concept to rituximab, which has been used off-label for refractory lupus for years.
Once kidney disease responds to treatment, maintenance therapy needs to continue for at least three years. Patients who started on mycophenolate generally stay on it, while those who started on cyclophosphamide are typically switched to mycophenolate or azathioprine for the long haul.
How Treatment Is Layered Over Time
Lupus treatment isn’t a single prescription. It’s a layered strategy that builds up or scales down based on how you’re doing. The simplest version is hydroxychloroquine alone for someone with mild disease. If that’s not enough, a low dose of prednisone gets added temporarily while a slower-acting immunosuppressant ramps up. Once the immunosuppressant takes effect, the goal is to taper steroids as low as possible. If standard immunosuppressants don’t do the job, a biologic gets layered on top.
This stepwise approach means your medication regimen will likely change over time, sometimes multiple times. Flares may require temporary increases in steroids. Periods of remission might allow your doctor to simplify your regimen. The overarching goals are to control disease activity, minimize steroid exposure, prevent organ damage, and keep you on the least amount of medication that keeps things stable. Most people with lupus end up on at least two medications simultaneously, with hydroxychloroquine as the constant anchor.